Bacterial meningitis is an infectious disease characterised by infection and inflammation of the meninges, which leads to significant morbidity and mortality worldwide. Even with early diagnosis and proper treatment, 8-15% of patients succumb to the disease within 24 to 48 hours of symptom onset. While meningitis can affect individuals of all ages, young children face the greatest risk. Newborns are particularly vulnerable to Group B streptococcus, while meningococcus, pneumococcus, and Haemophilus influenzae pose higher risks for young children. Young adults and adolescents are prone to meningococcal disease, whereas the elderly are at a higher risk of pneumococcal disease.
The Vivalytic Bacterial Meningitis panel provides the capability to identify six bacterial pathogens implicated in meningitis from a single test, improving screening processes and lowering costs. With minimal steps from sample collection to result, screening for meningitis on the Vivalytic is the most effective wait to contain and prevent spread, requiring no additional further lab equipment.
Key Benefits:
- Compared to the time-consuming traditional procedures, Vivalytic’s quick turnaround time of 30 minutes allows for the prompt and specific antibiotic treatment to be initiated immediately
- Convenient 4 step process from sample entry to results. Suitable for use in laboratory and non-laboratory settings
- Detection from a small CSF sample of only 200μl